Abstract TRAIL (TNF-related apoptosis-inducing ligand) has been shown to induce apoptosis by binding to TRAIL-R1 and -R2 death receptors, but not to TRAIL-R3 or -R4, its decoy receptors that lack the internal death domain. Osteoclasts (Ocs) are sensitive to TRAIL-induced apoptosis, and modulation of these receptors may change Oc sensitivity to TRAIL. Using human Oc cultures, we first investigated the gene expression profile of these receptors (TNFRSF10 -A, -B, -C, -D encoding TRAIL-Rs 1-4) by real time PCR after adding osteotropic factors during the last week of Oc cultures. We observed a significant decrease in the expression of TNFRSF10-A after the addition of TGFb, and an increase in that of TNFRSF10-A and -B post-PTH stimulation. Protein expression of TRAIL-R1 and -R3 was upregulated in the presence of MIP-1a, but down-regulated in the presence of TGFb (R1), TRAIL (R2) or OPG (R3). The percentage of Ocs expressing the TRAIL-R1 and/or -R2 at their surface was increased by MIP-1a and TRAIL, increased (R2) or decreased (R1) by TGFb, and the percentage expressing TRAIL-R3 was increased by MIP-1a, TRAIL and RANKL. Although significant, the magnitude of all these changes was of about 10-15%. While a direct correlation between these changes and TRAIL-induced Oc apoptosis was less clear, a protective effect was observed in Ocs that had been treated with OPG, and an additive effect in Ocs pre-treated with TRAIL or TGFb increased TRAIL sensitivity.
Introduction
Osteoclasts (Ocs) are multinucleated cells of hematopoietic origin, responsible for bone resorption. After carrying out this resorptive activity, Ocs undergo apoptosis. Regulation of the numbers of Oc precursors and mature Ocs via the induction of cell death is an important mechanism by which the number of active Ocs at any site is controlled, thus regulating bone resorption [1, 2] . Oc apoptosis occurs via extrinsic or intrinsic signaling [3] , via pathways including the TNF-related apoptosis-inducing ligand (TRAIL) pathway, which has been shown to be involved in human Oc apoptosis. Of the five human TRAIL receptors that have been identified, both TRAIL-R1 and TRAIL-R2 contain a functional ''death domain'' in their intracellular portion, unlike TRAIL-R3 and TRAIL-R4, which are decoy receptors unable to initiate apoptosis [4] . Finally, the fifth identified TRAIL receptor is the soluble decoy receptor OPG, that inhibits TRAIL-mediated apoptosis [5] . Oc-like cells express the decoy receptors TRAIL-R3 and TRAIL-R4, as well as TRAIL-R1 and TRAIL-R2, both of which are able to induce apoptosis in human Ocs upon binding TRAIL [6] [7] [8] . The binding of TRAIL to the death receptors leads to the formation of a death-inducing signaling complex (DISC), a combination of the intracellular adaptor Fas-associated death domain (FADD) and procaspases-8/10, to trigger the final apoptosis events. Depending on cell type, TRAIL-induced apoptosis may also require further signal amplification by the intrinsic/ mitochondrial pathway to occur [9] . The binding of TRAIL also promotes TRAIL-R1/-R2 internalization via both clathrin-dependent and clathrin-independent pathways. Besides activating caspases, TRAIL may stimulate intracellular kinase cascades, such as NF-jB, MAP kinases and protein kinase B (PBK)/Akt pathways via independent pathways, possibly mediated by the delayed formation of a secondary intracellular signaling complex [10] .
TRAIL-resistance is a common feature in cancer cells [11] . In multiple myeloma, bone marrow stroma promotes resistance to TRAIL in part by increasing the synthesis of the anti-apoptotic protein c-FLIP [12] or by increasing the NF-jB activity in myeloma cells [13] [14] [15] . Other factors such as proinflammatory cytokines like IL-8 and matrix metalloproteinases [16, 17] , RANKL (receptor activator of NF-jB ligand) [18] and OPG (osteoprotegerin) [19] have also been involved in the resistance to TRAIL-induced apoptosis in malignant cells [18, 19] . TRAIL resistance could also be a symptom of impaired transport of TRAIL-R1 and -R2 to the cell surface [20, 21] , or of an excessive expression of the decoy receptors [22] . Although the status of the TRAIL receptors does not always predict the TRAIL sensitivity of myeloma cells [23, 24] , new antineoplastic agents such Bortezomib or antileukemic drugs may restore and promote TRAIL-induced apoptosis, at least in part by up-regulating the expression of DR4 (TRAIL-R1) and DR5 (TRAIL-R2) on myeloma or leukemia cells [25] [26] [27] . In a previous study, we found that both decoy receptors (TRAIL-R3 and -R4) were strongly expressed in Ocs from myeloma bone lesions, whereas the expression of TRAIL-R1 and TRAIL-R2 was weaker [6] . These findings are consistent with data showing that Ocs generated in the presence of myeloma T-cells over-express TRAIL-R4, and display reduced expression of TRAIL-R1 [28] . These results suggest that the TRAIL-receptor profile could contribute to the high level of Oc survival/activity observed in myeloma, and emphasize the role of the bone microenvironment.
Various different mechanisms may therefore affect sensitivity to TRAIL-induced apoptosis, and modulation of the expression of TRAIL receptors may be one of them [22] . We therefore wondered whether local factors or cytokines that are overexpressed in bone diseases associated with high levels of bone resorption, such as RANKL/ OPG and MIP-1a (macrophage inflammatory protein-1a) in myeloma [29, 30] , TGFb in metastatic bone disease [31] , PTH in hyperparathyroid bone disease, as well as TRAIL itself, might be responsible for modulating TRAIL receptors in Ocs in a way that desensitizes them to apoptosis, and thus be part of the process that leads to an uncontrolled increase in osteoclastic bone resorption.
Materials and methods

Reagents
Optimized Eagle's minimum essential medium (Opti-MEM), penicillin, streptomycin, fungizone, glutamine, and fetal bovine serum (FBS) were purchased from Gibco (Burlington, QC). Ficoll-Plaque was purchased from Amersham Biosciences (Montreal, QC). Methocult GF H4534 (Iscove's MDM containing 1% methylcellulose,  30% FBS, 1% BSA, 10 -4 M 2-mercaptoethanol, 2 mM Lglutamine, 10 ng/ml recombinant human GM-CSF, 10 ng/ ml rhIL-3, and 50 ng/ml rhSCF) was purchased from StemCell Technologies (Vancouver, BC). Recombinant human M-CSF, GM-CSF, TRAIL, PTH, MIP-1a and OPG were purchased from R&D systems (Minneapolis, MN); rh-TGF-b1 was obtained from Peprotech (Rocky Hill, NJ); rabbit polyclonal antibodies against TRAIL-R1 (DR4) and TRAIL-R2 (DR5) came from Abcam (Cambridge, MA), rabbit polyclonal antibodies against TRAIL-R3 (DcR1) from Upstate biochemicals (Millipore, Billerica, MA), goat polyclonal antibodies against TRAIL-R4 (DcR2) from Santa Cruz (Santa Cruz, CA), and rabbit polyclonal antibodies against RANK (Chemicon, Inc, Temecula CA). LSAB2 staining kit was obtained from DAKO (Glostrup, Denmark). Soluble human RANKL was produced in our laboratory.
Cell cultures
Umbilical cord blood from normal pregnant women was obtained at delivery after obtaining informed consent. Mononuclear leukocyte suspensions were isolated from the cord blood by density-gradient centrifugation, and then washed, and suspended in Opti-MEM with antibiotics (penicillin 1 IU/ml, streptomycin 100 mg/ml, amphotericin B 0.5 mg/ml) and 2% (FBS) (Wisent, Montreal, Canada). They were plated at a density of 3 9 10 6 cells/ml. After incubating overnight, the cells were washed to remove nonadherent cells. The selected cord blood monocytes (CBMs) were cultured for 10 days in Methocult, and then for a further 2 weeks in Opti-MEM supplemented with M-CSF (25 ng/ml) and RANKL (100 ng/ml). In some cultures, RANKL (100 and 200 ng/ml), MIP1a (50 and 100 ng/ml), TRAIL (2.5 and 25 ng/ml), OPG (10 and 50 ng/ml), TGFb (1 and 10 ng/ml) or PTH (10 and 25 ng/ml) were added in the last week of the culture period. The medium was changed twice weekly. We had previously shown that fully differentiated Ocs are formed under these conditions [6] .
Evaluation of bone resorption in cultures performed on cortical bone slices After expansion in Methocult, CBMs were settled on devitalized bone slices, and then cultured for a further 2 weeks under the same conditions as above. The bone slices were then removed, washed with sodium hydroxide and distilled water, sonicated to remove cell debris, and stained with 1% toluidine blue containing 1% sodium borate. Bone resorption was determined under optical light microscopy with epi-illumination.
Quantitative PCR
Total RNA was extracted using Trizol Reagent (Invitrogen, Burlington, ON), followed by 2-propanol precipitation of total RNA. RNA quality and the presence of contaminating genomic DNA was verified as previously described [32] . 1 lg of total RNA was used to perform cDNA synthesis and quantitative PCR amplification. Human primers of TNFRSF10-A, -B, -C, and -D, TRAIL receptor genes encoding TRAIL-R1, -R2, -R3, and -R4, respectively, were generated using RefSeq database, and validated by the RNomics platform of our institution. Quantitative PCR (qPCR) reactions were performed in 10 ll in 96 well plates on a Realplex2 thermocycler (Eppendorf, Mississauga, ON) with 5 ll of 29 FastStart Universal SYBR Green Master Mix (Roche Diagnostics), 10 ng (3 ll) cDNA, and 200 nM final (2 ll) primer pair solutions. All samples were run in triplicate. Relative expression levels were calculated using the qBASE framework [33] and the geometric average of three reference housekeeping genes (MRPL19-mitochondrial ribosomal protein L19, PUM1-pumilio homolog 1, RPL13A-ribosomal protein L13a), and normalized to allow for technical and experimental errors.
Western blot analysis
At the end of the Oc cultures, the cells were washed twice and lysed for 20 min on ice in lysis buffer (150 mM NaCl, 50 mM TRIS, 1% NP40, 0.5% deoxycholate, 10 mM sodium pyrophosphate, 0.1% SDS, 5 mM EDTA). Fifty micrograms of total proteins were separated by SDS-PAGE, and transferred to a PVDF membrane (Millipore, Billerica, MA). The membrane was blocked with 5% skimmed milk in TBS-Tween, and incubated overnight at 4°C with the primary antibody. For these experiments we used primary antibodies against TRAIL-R1 (1:400), TRAIL-R2 (1:350), TRAIL-R3 (1:250) and TRAIL-R4 (1:100). Anti-actin antibodies were used as a loading control. The membranes were then washed before being incubated for 1 h at room temperature with an HRP-conjugated anti-mouse, anti-goat or anti-rabbit antibody. Bound antibodies were visualized by an enhanced chemiluminescence (ECL) detection system (Amersham Biosciences, Piscataway, NJ, USA). All bands were measured by densitometry, and normalized for the optical density of the actin bands after stripping and reblotting the membranes (NIH ImageJ software, Bethesda, Maryland, USA).
Immunocytochemistry analysis
After 3 weeks of culture in 8-chamber Labtecks, mature Ocs were fixed with 1% paraformaldehyde in PBS; nonspecific binding sites were blocked with 5% skimmed milk, and the cells were then incubated overnight at 4°C with the primary antibody directed against human TRAIL-R1 (1:150), TRAIL-R2 (1:350), TRAIL-R3 (1:250) or RANK (1:250) or with the same concentration of normal rabbit serum. After three washes, the specimens were exposed to 3% H 2 O 2 in PBS for 5 min to inactivate any endogenous peroxidase activity. Sequential incubations were then performed with biotinylated secondary antibody (45 min) and peroxidase-labeled streptavidin (45 min) from the biotinstreptavidin-peroxidase LSAB2 kit. Specific labeling was revealed with AEC chromogen, which produced a red precipitate where peroxidase had been bound. In order to identify multinucleated cells, the specimens were counterstained with hematoxylin.
Study of apoptosis
Oc apoptosis was determined after removing M-CSF and RANKL, as well as reducing FBS to 1% in the Opti-MEM for 24 h prior to the experiments. TRAIL 10 ng/ml was then added for a further 24 h where appropriate. The TACS Blue Label kit (Trevigen) was then used to detect and quantify apoptosis. The cells were fixed, washed and permeabilized in an ethanol:acetic acid (2:1) solution for 10 min at -20°C. They were then washed thoroughly with PBS to rehydrate them. Biotinylated nucleotides were incorporated by terminal deoxynucleotidyl transferase (TdT) for 2 h at 37°C. Streptavidin-HRP conjugate was then added (45 min), followed by the substrate, TACS Blue Label (10 min). The resulting enzymatic reaction generated an insoluble, blue precipitate where DNA fragmentation had occurred. The specimens were then counterstained with Nuclear Fast Red for 10 min at room temperature, in order to identify any multinucleated cells displaying nuclear fragmentation. The stained samples were examined under a light microscope, and the multinucleated cells counted manually.
Statistical analysis
Results are expressed as mean ± standard deviation (SD), and the significance was determined by a paired Student's t test, or a one-way ANOVA with Bonferroni post-test where applicable. Statistical significance was defined as P \ 0.05. (Fig. 1a, b) , and results are expressed as the mean proportion of positive MNC ± SD, in 3 experiments. The proportion of RANK-positive cells was 80% ± 3.5 of the MNCs. When CBMs were cultured on the surface of cortical bone, resorption pits covering most of the bone surface area were formed (Fig. 1c, d ). In addition, Western blotting showed that STRO-1, a mesenchymal marker, was not present amongst the whole-culture extracted proteins (1-E). These findings make it clear that we have a reliable model for generating cells with the phenotypic markers of mature human Ocs. Although the population was heterogeneous towards the end of the culture, containing multinucleated Ocs as well as mononuclear cells of the monocyte-macrophage population [34] , it was devoid of any mesenchymal component.
TRAIL receptor gene expression profile in Oc cultures
In order to search for differences in the expression of TRAIL receptor genes, we investigated their relative gene expression profile in Oc cultures derived from CBMs, cultured for 3 weeks with Methocult and then RANKL and MCSF. To these cultures RANKL (100 and 200 ng/ml), MIP1a (50 and 100 ng/ml), TRAIL (2.5 and 25 ng/ml), OPG (10 and 50 ng/ml), TGFb (1 and 10 ng/ml) or PTH (10 and 25 ng/ml) had also been added during the last week of this culture period. After RNA extraction, the relative expression of the four TRAIL-receptors was determined using real-time PCR, and the results are shown in Fig. 2a .
Compared to untreated cultures, TNFRSF10A was significantly downregulated in the presence of 10 ng/ml TGFb and upregulated in the presence of 10 ng/ml PTH. TNFRSF10B was significantly upregulated in the presence of PTH at both 10 and 25 ng/ml (Figure 2b ).
Western blot analysis for TRAIL receptor expression
To further investigate TRAIL receptor expression, we performed Western blot analyses of proteins extracted from whole Oc cultures at the end of the 3-week period (Fig. 3a) .
As shown in Fig. 3b , the expression of TRAIL-R1 was significantly increased in the presence of MIP-1a at 100 ng/ ml (P = 0.03) compared to untreated cultures, whereas it was reduced in the presence of TGFb at 10 ng/ml, but only when compared to the lowest dose of TGFb (P = 0.05, 10 vs. 1 ng/ml). TRAIL-R2 was significantly reduced in the presence of TRAIL at 25 ng/ml (P = 0.03), and TRAIL-R3 was increased in the presence of MIP-1a at 100 ng/ml (P = 0.03), but reduced in the presence of OPG at 10 ng/ml (P = 0.04). No changes in TRAIL-R4 expression were observed in the presence of any of these factors. PTH and RANKL did not have any effect on TRAIL receptor expression in these experiments (data not shown).
Immunocytochemistry used to study the membrane expression of the TRAIL receptors
As Oc cultures include non-osteoclastic cells, multi-or mononuclear cells of the monocyte-macrophage lineage, we also studied the expression of the TRAIL receptors by immunocytochemistry (Fig. 4a) . Using specific antibodies against each TRAIL receptor, we evaluated the number of multinucleated cells identified as Ocs expressing TRAIL-R1, -R2 or -R3 (Fig. 4b) . The number of Ocs expressing TRAIL-R1 was significantly higher in the presence of MIP1a at a concentration of 50 or 100 ng/ml (P \ 0.01), and in the presence of TRAIL at the lowest concentration (P \ 0.01), whereas it was lower in the presence of 10 ng/ml TGFb (P \ 0.05). The number of Ocs expressing TRAIL-R2 was significantly higher in the presence of MIP1a, TRAIL or TGFb at the highest concentrations (P \ 0.05 for all). The number of Ocs expressing TRAIL-R3 was significantly higher in the presence of MIP-1a at 100 ng/ml (P \ 0.001), of TRAIL at 25 ng/ml (P \ 0.01), and of RANKL at both 100 and 200 ng/ml (P \ 0.05), but was lower in the presence of TGFb at the lowest concentration (1 ng/ml, P \ 0.01). Neither OPG nor PTH affected any of the TRAIL-receptors at this level. TRAIL-R4 was not investigated in these experiments because its expression did not vary at either the gene expression level or the protein level under our conditions.
TRAIL-induced apoptosis
To evaluate the functional relevance of these changes in the expression profile of the TRAIL receptors, we studied Oc apoptosis in the presence of TRAIL (10 ng/ml) after pre-incubating the Oc cultures with target cytokines (Fig. 5a ). As expected, TRAIL significantly increased the basal rate of Oc apoptosis after 48 h of serum deprivation (Fig. 5b) . The addition of TRAIL to cultures that were already TRAIL-stimulated further increased this rate. In the presence of MIP-1a, the rate of TRAIL-induced apoptosis did not change, and the pre-treatment with MIP-1a did not affect the TRAIL-induced rate of Oc apoptosis. As expected, TGFb independently increased the rate of Oc apoptosis, but pre-incubation with TGFb also significantly increased the TRAIL-induced apoptosis. Although RANKL decreased Oc apoptosis, pretreatment with high doses of RANKL did not induce any changes in the TRAIL-induced apoptosis. However, OPG displayed a protective effect, as the level of TRAIL-induced Oc apoptosis was significantly lower after the culture had been pre-treated with OPG (50 ng/ml). Pre-incubating Oc cultures with PTH did not induce any change in the TRAIL-induced apoptosis rates.
Discussion
The expression of TRAIL receptors has been previously established at the surface of mature human Ocs [6, 7] , during Oc differentiation [35] , and in hematopoietic cord blood progenitors [36] , and may vary depending on the stage of differentiation [7] . However, this is the first study to investigate the effects of Oc modulators on the expression of all TRAIL receptors not only at the mRNA and protein levels, but also at the Oc surface, and to compare their expression to TRAIL-induced apoptosis. Studying mature human Ocs differentiated from CBMs, we During the last week of the culture period, CBM cultures were treated with RANKL (100 and 200 ng/ml), MIP1a (50 and 100 ng/ml), TRAIL (2.5 and 25 ng/ml), OPG (10 and 50 ng/ ml), TGFb (1 and 10 ng/ml) or PTH (10 and 25 ng/ml). a The expression of four TRAIL receptors (TRAIL-R1, -R2, -R3, and -R4) was analyzed by Western blot using proteins extracted from the whole Oc culture. Results of MIP-1a 1, TGFb (10 ng/ml), and TRAIL (25 ng/ml) are shown. b The intensity of the bands was analyzed using NIH ImageJ Software for 3 independent experiments (n = 2 for TRAIL-R2 in presence of OPG), protein expressions were normalized relative to the respective actin intensity, and the results are expressed as the expression relative to that of the untreated cells (mean ± SD) (paired Student's t test, *P \ 0.05, treated vs. untreated, # low vs. high dose). Results of MIP-1a, TRAIL, OPG and TGFb are shown demonstrated here that Oc regulators that have been associated with osteolytic conditions may undergo modulation of the pattern of expression of the TRAIL receptors, at the mRNA, protein, or surface level. We also observed that individually most of these changes did not have any clear effect on TRAIL-induced apoptosis, probably because of their low absolute magnitude. However, pre-treatment with TRAIL and TGFb significantly increased TRAIL-induced apoptosis, which was decreased by the presence of OPG. Studying the gene expression profile of the TRAIL receptors from whole-culture RNA, we observed that PTH upregulated the expression of the TNFRSF10A and TNFRSF10B genes, and that TGFb downregulated the expression of the TNFRSF10A. However, in protein Fig. 4 Expression of the TRAIL receptors (TRAIL-R1, -R2, -R3) at the Oc surface. During the last week of the culture period, CBM cultures were treated with RANKL (100 and 200 ng/ml), MIP1a (50 and 100 ng/ml), TRAIL (2.5 and 25 ng/ml), OPG (10 and 50 ng/ml), TGFb (1 and 10 ng/ml) or PTH (10 and 25 ng/ml). a At the end of the Oc cultures, the expression of the TRAIL receptors was evaluated by immunocytochemistry using specific antibodies. Polyclonal rabbit IgGs were used as negative controls. Photographs in untreated CBM cultures are provided. Positive Ocs are delineated by black arrows (9200). b The percentage of labeled cells was determined for each TRAIL R type. Results are expressed as the percentage of labeled to total Ocs (mean ± SD) in 3 independent experiments. The results are shown for MIP-1a, TRAIL, RANKL and TGFb. (paired Student'sexpression assays from whole-culture lysates PTH did not have any impact on these receptors, although TGFb did reduce TRAIL-R1 expression. In addition, protein expression of TRAIL-R1 and -R3 was upregulated in the presence of MIP-1a, but down-regulated in the presence of TRAIL (TRAIL-R2) or OPG (TRAIL-R3) without any changes in the corresponding mRNA expression. Discrepancy between protein and mRNA expression have been related to the existence of various levels of regulation during protein synthesis, such as post-transcriptional, translational, or post-translational regulation [37] . Several studies performed in prokaryote or eukaryote systems indicate that differential expression of mRNAs explain at most 40% of the differential expression of proteins both at steady-state and after cell stimulation [37, 38] . Besides, our culture model also includes non-Oc cells, which may have induced variability and misinterpretation with respect to the Oc population. Indeed, in long-term cultures of CBMs following Methocult to enhance the Oc precursor population, a contingent of mononuclear cells persists which could be divided into two monocyte/macrophage phenotypes: CD14
? NSE ? or CD11b ? NSE ? CD14 - [34] . We therefore At the end of the CBM cultures, hrTRAIL (10 ng/ml) was added for 24 h before apoptosis was evaluated. To quantify the number of apoptotic osteoclasts, TACS Blue labeling was used, resulting in blue staining of the nuclei of the apoptotic cells (positive multinucleated cells are delineated by empty arrows, while non-apoptotic nuclei were stained pink/red (black arrows) with a Nuclear Fast red counterstain. a The figure shows a negative control (CBM cultures at 3 weeks without starvation), a CBM culture primed to study apoptosis and treated with TRAIL (10 ng/ml) for 24 h or with staurosporin (1 lM) as a positive control (9100). b During the last week of the culture period, CBM cultures were treated with TRAIL (25 ng/ml), MIP-1a (100 ng/ml), TGFb (10 ng/ml), RANKL (200 ng/ml), OPG (50 ng/ml), or PTH (10, 25 ng/ml), and an apoptosis assay was performed as described.
Results are expressed as the percentage of apoptotic osteoclasts (Ocs) (mean ± SD) in 4-6 independent experiments. (paired Student's t test, *P \ 0.05, **P \ 0.01, ***P \ 0.001 vs. untreated controls,°P \ 0.05,°°P \ 0.01 vs. TRAIL-stimulated after same pre-treatment, # P \ 0.05 vs. TRAIL-stimulated controls)
use single-cell assays, such as immunocytochemistry (ICC) and in situ TUNEL, to circumvent the potential impact of the monocyte/macrophage population.
In ICC experiments using the highest dose of each factor, the percentage of Ocs expressing the death receptors TRAIL-R1 and/or -R2 at their surface was increased by MIP-1a and TRAIL, and the percentage expressing decoy receptor TRAIL-R3 was increased by MIP-1a, TRAIL and RANKL. On the other hand TGFb reduced the percentage of Ocs expressing TRAIL-R1, while increasing that expressing TRAIL-R2. Although significant, the magnitude of all these changes was about 10-15%, which might have been not enough alone to have any impact of the resultant TRAIL-induced apoptosis. In addition, MIP-1a, TRAIL and RANKL affected both death and decoy receptor expression in the same way. Indeed, these changes were not associated with any change in the TRAIL-induced apoptosis post-MIP1a treatment. However, pre-treatment with either TRAIL and TGFb significantly increased the TRAIL-induced Oc apoptosis. TRAIL was previously shown to stimulate expression of its own receptor (TRAIL-R2) in human Oc cultures at a higher dose (500 ng/ml) [7] , and to modulate the subcellular distribution of its death/ decoy receptors [39] . As TRAIL and TGFb are both well known Oc-apoptosis inducers, and because they may act in different ways to modulate caspase-driven activation [9, 40] , the possibility that their positive effects on TRAILinduced apoptosis were attributable to an additive effect must also be considered. RANKL also increased the Oc surface expression of TRAIL-R3, without any change in TRAIL-induced apoptosis. However, RANKL is an Oc survival factor via various different pathways, mainly involving the activation of NF-jB [41] , our model which is reliant on RANKL to induce Oc differentiation could have therefore not allowed us to detect the potential impact of these changes. Finally, OPG, which interacts with TRAIL itself, decreased the rate of TRAIL-induced apoptosis, without changes in the cell surface expression, underlying a likely direct protective effect against TRAIL-induced Oc apoptosis [42] .
The effects of TGFb on Oc apoptosis are controversial. We have previously reported that in human Oc cultures, TGFb increased Oc apoptosis by upregulating Bim [43] . In murine bone marrow cultures, this factor was found to be protective, and to inhibit Oc apoptosis [44] . Speciesspecific signaling cascades may be involved in these differences, as well as some of the varied pathways involved in TGFb signalling. For instance, TGFb enhances TIEG1 expression (TGF-b Inducible Early Gene-1), which has been reported to stimulate Oc differentiation by increasing RANK and NFATc1, but also to decrease mature Oc survival by inhibiting the Bcl2, Akt and MEK pathways [40] .
MIP-1a, an Oc activating factor implicated in lytic diseases of bone, and particularly in myeloma bone disease, was another potential candidate as a modulator of TRAIL-R expression. MIP-1a induces OC formation in murine models through CCR1 and CCR5 without RANKL stimulation via the activation of the MEK/ERK/c-Fos pathway, and inhibition of the p38MAPK pathway [45] . MIP-1a is produced by myeloma plasma cells, and is known to stimulate Oc formation and bone resorption in human bone marrow cultures [29] . Interestingly, it has been shown that MIP-1a directly affects cell signaling pathways such as the activation of the Akt/protein kinase B, and the MAPK pathway in myeloma cells through CCR5, mediating their growth, survival and migration [46] . It had not yet been shown whether MIP-1a is capable of inducing the same survival effects in human Ocs, however our results would indicate that MIP-1a does not impart lasting effects on Oc apoptosis.
There is now growing evidence suggesting that changes in the regulation of Oc death may contribute to clinically important bone diseases, not only in conditions involving malignant osteolysis, such as multiple myeloma [6, 28] , but also in metabolic bone diseases such as osteoporosis [47] and Paget's disease of bone [48] , as well as in the subchondral bone resorption observed in rheumatoid arthritis [49] [50] [51] . Understanding the regulation of Oc apoptosis in these conditions is thus of major importance. While in our present study, discrepancies were observed between the changes observed at different levels, without any obvious correlation with the resultant TRAIL-induced apoptosis, we believe that these different techniques (mRNA, protein, cell surface expression) are complementary, and provide an important integrated analysis for understanding biological systems. Modulating TRAIL receptor expression is one of many ways to affect TRAIL-induced Oc apoptosis, and by highlighting the impact of osteolytic factors on TRAIL receptor expression at different levels, our results contribute to our general knowledge about the complex process of Oc apoptosis. This way of regulating Oc apoptosis does not, however, seem to be a major contributor in the regulation of human Oc apoptosis, at least in our in vitro model.
